Frequency and Temporal Evolution of COVID-19 Vaccination Rate Among Oncological Patients Undergoing 18F-FDG-PET

15 Pages Posted: 6 Jan 2022

See all articles by Stephan Martin Skawran

Stephan Martin Skawran

University Hospital Zurich - Department of Nuclear Medicine

Helen Schiesser

University Hospital Zurich - Department of Nuclear Medicine

Alexander Maurer

University Hospital Zurich - Department of Nuclear Medicine

Thomas Sartoretti

University Hospital Zurich - Department of Nuclear Medicine

Manuel Dittli

University Hospital Zurich - Department of Nuclear Medicine

Cäcilia Mader

University Hospital Zurich - Department of Nuclear Medicine

Alessandra Curioni-Fontecedro

University of Zurich - Department of Medical Oncology and Hematology

Christoph Berger

University of Zurich

Martin W. Huellner

University Hospital Zurich - Department of Nuclear Medicine

Michael Messerli

University Hospital Zurich - Department of Nuclear Medicine

Abstract

Purpose: To evaluate the rate and temporal evolution of vaccination against COVID-19 in a Swiss oncological cohort of patients undergoing 18F-FDG-PET.

Methods: History of prior complete vaccination against COVID-19 of patients undergoing oncological 18F-FDG PET/CT between February and September 2021 (n=2613) was taken. Descriptive statistics of vaccination rate were applied. Vaccination rate was compared with national data from the Swiss Federal Office of Public Health. Subgroup differences in temporal evolution of vaccination rate were analyzed by fitting a generalized linear model and determined by significant interaction between, gender, oncological diagnosis, and month of examination.

Results: Rate of complete vaccination against COVID-19 steadily increased and reached 81 % in September 2021. The fraction of vaccinated patients in the oncological cohort was higher than in the overall Swiss population throughout the study period. Month of exam (p<0.001) and suspicion for malignant neoplasm (SMN, p=0.02) were significant predictors of the vaccination rate. Vaccination rate was lower in SMN.

Conclusion: Vaccination rate against COVID-19 in a Swiss oncological cohort increased steadily from February to September 2021 and was higher than in the general population. Vaccination rate was significantly lower in patients with SMN, probably as these patients do not have an established diagnosis of cancer at the time of imaging.

Note:
Funding: Dr. Stephan Skawran is supported by a grant from the Palatin-Foundation, Switzerland. Dr. Michael Messerli received a research grant from the Iten-Kohaut Foundation, Switzerland. Dr. Michael Messerli and Dr. Martin W. Huellner are supported by a grant from the CRPP AI Oncological Imaging Network of the University of Zurich. Dr. Martin W. Huellner received grants from GE Healthcare and a fund by the Alfred and Annemarie von Sick legacy for translational and clinical cardiac and oncological research.

Declaration of Interests: The University Hospital of Zurich holds a research agreement with GE Healthcare (unrelated to current study). Other than that, the authors declare that they have no competing interests.

Ethics Approval Statement: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This retrospective study protocol was approved by the local institutional ethics committee (Kantonale Ethikkommission Zürich) and written informed consent for the scientific use of medical data was obtained from all patients.

Trial Registration: Trial No. BASEC-Nr. 2021-00444.

Keywords: COVID-19, Vaccination, Fluordeoxyglucose, Cancer, Oncological Imaging

Suggested Citation

Skawran, Stephan Martin and Schiesser, Helen and Maurer, Alexander and Sartoretti, Thomas and Dittli, Manuel and Mader, Cäcilia and Curioni-Fontecedro, Alessandra and Berger, Christoph and Huellner, Martin W. and Messerli, Michael, Frequency and Temporal Evolution of COVID-19 Vaccination Rate Among Oncological Patients Undergoing 18F-FDG-PET. Available at SSRN: https://ssrn.com/abstract=3990525 or http://dx.doi.org/10.2139/ssrn.3990525

Stephan Martin Skawran (Contact Author)

University Hospital Zurich - Department of Nuclear Medicine ( email )

Raemistrasse 100
Zürich, 8091
Switzerland

Helen Schiesser

University Hospital Zurich - Department of Nuclear Medicine ( email )

Raemistrasse 100
Zürich, 8091
Switzerland

Alexander Maurer

University Hospital Zurich - Department of Nuclear Medicine ( email )

Raemistrasse 100
Zürich, 8091
Switzerland

Thomas Sartoretti

University Hospital Zurich - Department of Nuclear Medicine ( email )

Raemistrasse 100
Zürich, 8091
Switzerland

Manuel Dittli

University Hospital Zurich - Department of Nuclear Medicine ( email )

Raemistrasse 100
Zürich, 8091
Switzerland

Cäcilia Mader

University Hospital Zurich - Department of Nuclear Medicine ( email )

Raemistrasse 100
Zürich, 8091
Switzerland

Alessandra Curioni-Fontecedro

University of Zurich - Department of Medical Oncology and Hematology ( email )

Zurich
Switzerland

Christoph Berger

University of Zurich ( email )

Rämistrasse 71
Zürich, CH-8006
Switzerland

Martin W. Huellner

University Hospital Zurich - Department of Nuclear Medicine ( email )

Raemistrasse 100
Zürich, 8091
Switzerland

Michael Messerli

University Hospital Zurich - Department of Nuclear Medicine ( email )

Raemistrasse 100
Zürich, 8091
Switzerland

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
28
Abstract Views
183
PlumX Metrics